MedElevator
Войти в исследования Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2026
Efficacy and safety of a radiographic severity-stratified all-oral short treatment regimen for multidrug/rifampicin-resistant tuberculosis in China: an open-label, multicentre, randomised controlled, noninferiority trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sun Wen-Wen, Ren Fei, Yang Fu-Ping, Zhang Shao-Jun, Wang Hua, Su Fei-Fei, Yin Ming-Dan, Jiang Xing-Mei, Chen Jian-Cai, He Wei-Guo, Zeng Zhong, Chen Yu, Zhang Xiang-Rong, Fan Lin
Аннотация
OBJECTIVES: This study evaluated the efficacy and safety of a radiographic severity-stratified, all-oral short-course treatment regimen (STR) for multidrug/rifampicin-resistant tuberculosis in China.
METHODS: Enrolled participants were randomly divided (2:1) to receive either an all-oral STR or an 18-month regimen based on the 2019 WHO guidelines as the control. The STR group was divided into three subgroups according to radiographic severity scores. The primary efficacy endpoint was a favourable treatment outcome up to 6 months after discontinuation. The primary safety endpoint was grade ≥3 adverse events (AEs) during the study period. A prespecified noninferiority margin of <12 percentage points were used for the between-group difference in favourable outcomes.
RESULTS: A total of 259 participants were randomly divided, with 173 and 86 assigned to the STR and control groups, respectively. In the modified intention-to-treat population, the favourable treatment outcome rate was 87.1% (148/170) in the STR group and 81.5% (66/81) in the control group. The between-group difference was 5.6 percentage points (95% CI, -5.7 to 13.8; p 0.03 for noninferiority). In the per-protocol population, the favourable treatment outcome rate was 89.0% (146/164) in the STR group and 83.1% (64/77) in the control group. The between-group difference was 5.9 percentage points (95% CI, -7.9 to 11.7; p 0.02 for noninferiority). Grade ≥3 AEs occurred significantly less often in the STR group than in the control group (27.7% vs. 43.0%, p < 0.01).
CONCLUSIONS: The radiographic severity-stratified STR was noninferior to the traditional longer regimen in achieving favourable treatment outcomes and demonstrated better safety.
METHODS: Enrolled participants were randomly divided (2:1) to receive either an all-oral STR or an 18-month regimen based on the 2019 WHO guidelines as the control. The STR group was divided into three subgroups according to radiographic severity scores. The primary efficacy endpoint was a favourable treatment outcome up to 6 months after discontinuation. The primary safety endpoint was grade ≥3 adverse events (AEs) during the study period. A prespecified noninferiority margin of <12 percentage points were used for the between-group difference in favourable outcomes.
RESULTS: A total of 259 participants were randomly divided, with 173 and 86 assigned to the STR and control groups, respectively. In the modified intention-to-treat population, the favourable treatment outcome rate was 87.1% (148/170) in the STR group and 81.5% (66/81) in the control group. The between-group difference was 5.6 percentage points (95% CI, -5.7 to 13.8; p 0.03 for noninferiority). In the per-protocol population, the favourable treatment outcome rate was 89.0% (146/164) in the STR group and 83.1% (64/77) in the control group. The between-group difference was 5.9 percentage points (95% CI, -7.9 to 11.7; p 0.02 for noninferiority). Grade ≥3 AEs occurred significantly less often in the STR group than in the control group (27.7% vs. 43.0%, p < 0.01).
CONCLUSIONS: The radiographic severity-stratified STR was noninferior to the traditional longer regimen in achieving favourable treatment outcomes and demonstrated better safety.